Surfactant Treatment
Surfactant Treatment - Related Videos
09:34
Extraction and Characterization of Surfactants from Atmospheric Aerosols
0 Views •
Cited by 26 •
2017
Methods are presented for the targeted extraction of surfactants present in atmospheric aerosols and the determination of their absolute concentrations and surface tension curves in water, including their Critical Micelle Concentration (CMC).
07:20
Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome (ARDS)
0 Views •
Cited by 21 •
2016
Repeated pulmonary lavages in anesthetized pigs induce lung injury resembling major aspects of human acute respiratory distress syndrome (ARDS). For this purpose the lungs are repeatedly lavaged with 0.9% saline at 37 °C. The goal of the protocol is a reproducible mitigation of gas exchange and hemodynamics for research in ARDS.
10:28
Experimental Measurement of Settling Velocity of Spherical Particles in Unconfined and Confined Surfactant-based Shear Thinning Viscoelastic Fluids
0 Views •
Cited by 15 •
2014
This paper demonstrates the experimental procedure to measure terminal settling velocities of spherical particles in surfactant-based shear thinning viscoelastic fluids. Fluids over a wide range of rheological properties are prepared and settling velocities are measured for a range of particle sizes in unbounded fluids and fluids between parallel walls.
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
0 Views •
Cited by 26 •
2013
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe psoriasis.
06:22
Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)
0 Views •
Cited by 5 •
2021
A combination of surfactant washout using 0.9% saline (35 mL/kg body weight, 37 °C) and high tidal volume ventilation with low PEEP to cause moderate ventilator induced lung injury (VILI) results in experimental acute respiratory distress syndrome (ARDS). This method provides a model of lung injury with low/limited recruitability to study the effect of various ventilation strategies for extended periods.
FAQs
Surfactant composition can shape how biological surfaces behave during infection-related processes. Differences in the balance of surface-active molecules may affect barrier function, inflammatory responses, pathogen clearance, and responses to therapeutic treatment. Examining composition therefore helps researchers connect physicochemical properties at interfaces with downstream immunological and infectious outcomes, rather than treating all surfactant preparations as functionally identical.
Phospholipids provide the surface-active component that supports spreading and reduces alveolar surface tension, while associated proteins can interact with pathogens and innate immune components. Studying these elements separately or together helps clarify whether an observed effect reflects interface modification, direct pathogen interaction, or coordination with host defenses. This distinction is important when interpreting experimental formulations.
Lowering alveolar surface tension matters because it improves surfactant spreading and lung compliance, linking interface chemistry to respiratory function. In infection research, this physical effect provides a physiological context for examining how altered surfactant conditions may influence barrier behavior, inflammation, and pathogen clearance. The same treatment can therefore be evaluated for both biophysical and immune-related consequences.
Researchers can use experimental surfactant formulations as systems for examining microbial adhesion at biological interfaces. They can then relate differences in adhesion to formulation composition and to associated changes in membrane disruption or host-pathogen interactions. This approach connects an early infection-related event, microbial contact with a surface, to broader questions about barrier function and pathogen clearance.
Surfactant treatment can support studies of membrane disruption by examining how surface-active formulations affect pathogen-associated interfaces. In parallel, investigators can examine host-pathogen interactions and the involvement of innate immune components. Considering these mechanisms together helps distinguish direct effects on microbial or biological membranes from effects mediated through host responses, strengthening interpretation of infection-related experimental outcomes.
Pulmonary delivery is a relevant application when researchers need to examine how surfactant formulations behave in the respiratory system or influence therapeutic responses. Such studies can relate formulation properties to spreading, lung compliance, barrier function, inflammation, and pathogen clearance. The approach is especially informative in immunology and infection because delivery, tissue behavior, and host defense are interconnected.